Celldex Therapeutics Inc (NASDAQ: CLDX) stock enjoyed a major increase of 11.6% on 7/25/24. The shares closed at $43.86. Moreover, trading volume in this advance was unusually high at 157% of normal. The stock has been strong relative to the market over the last nine months and has risen 13.1% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, CLDX is expected to continue to be a modest Value Builder.
Celldex Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Celldex Therapeutics has a very low Appreciation Score of 6 but a slightly positive Power Rating of 64, producing the Negative Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment